Ibrahim Raphael, MD
Pulmonary Disease · Wichita, KSNPI 1275943144
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (53.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.2% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $8,066, 4.4 times the $1,817 reported in 2019.
Across 126 payments — averaging $102.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Inari Medical, Inc.$2K
- BD$493
- AbbVie$290
- Actelion Pharmaceuticals US, Inc.$252
- AstraZeneca$221
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2,84822%
- Food & beverage$3,13024%
- Education$7,00054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $7,944 |
| Inari Medical, Inc. | 10 | $2,322 |
| BD | 24 | $493 |
| AbbVie | 12 | $290 |
| Actelion Pharmaceuticals US, Inc. | 7 | $252 |
| AstraZeneca(2 entities) | 11 | $221 |
| Boehringer Ingelheim | 7 | $211 |
| Inspire Medical Systems, Inc. | 2 | $176 |
| Jazz Pharmaceuticals Inc. | 4 | $153 |
| United Therapeutics Corporation | 5 | $151 |
| Pulmonx Corporation | 1 | $122 |
| Bayer | 6 | $103 |
| Merck | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| La Jolla Pharmaceutical Company | 3 | $60 |
| Portola Pharmaceuticals, LLC | 2 | $59 |
| Vifor Pharma, Inc. | 3 | $54 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| GSK | 3 | $44 |
| Gilead | 1 | $29 |
| Novartis | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,977 in reported general payments places this provider in the 80th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $36,987 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $16,803 |
| EliquisApixaban | 19 | $14,003 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $13,841 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,693 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,763 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,252 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,636 |
| Arnuity ElliptaFluticasone Furoate | 20 | $4,228 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $3,325 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,142 |
| Azelastine Hcl | 32 | $691 |
| Pregabalin | 23 | $494 |
| Fluticasone Propionate | 11 | $174 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $44 | $65,820111 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $221 | $22,44037 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $211 | $19,94540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Victor SalloumWichita$14K
- Nader EldikaWichita$9K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.